1. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study). (January 2020) Authors: Pautier, P.; Penel, N.; Ray-Coquard, I.; Italiano, A.; Bompas, E.; Delcambre, C.; Bay, J.-O.; Bertucci, F.; Delaye, J.; Chevreau, C.; Cupissol, D.; Bozec, L.; Eymard, J.-C.; Saada, E.; Isambert, N.; Guillemet, C.; Rios, M.; Piperno-Neumann, S.; Chenuc, G.; Duffaud, F. Journal: European journal of cancer Issue: Volume 125(2020) Page Start: 31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗